Literature DB >> 12269555

Observations on haematological and cardiovascular effects of erythropoietin treatment in multiple system atrophy with sympathetic failure.

Andrea Sylvia Winkler1, Sabine Landau, Peter Watkins, K Ray Chaudhuri.   

Abstract

Symptomatic autonomic neuropathy and in particular sympathetic failure mediated postural hypotension often accompanies Multiple System Atrophy (MSA). Release of erythropietin is under sympathetic control and we and others have previously reported that severe autonomic failure may be associated with a normocytic normochromic anaemia and erythopietin (EPO) deficiency. In this paper we describe the haematological, cardiovascular and clinical observations on a patient with MSA and severe symptomatic autonomic neuropathy who had haematological and clinical improvement (substantial increase in standing blood pressure) following subcutaneous EPO treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12269555     DOI: 10.1007/s10286-002-0009-y

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN: 0959-9851            Impact factor:   4.435


  5 in total

Review 1.  Management of neurogenic orthostatic hypotension in patients with autonomic failure.

Authors:  Christoph Schroeder; Jens Jordan; Horacio Kaufmann
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

2.  Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia.

Authors:  Robert E Schmidt; Dongyan Feng; Qiuling Wang; Karen G Green; Lisa L Snipes; Michael Yamin; Michael Brines
Journal:  Exp Neurol       Date:  2011-08-18       Impact factor: 5.330

Review 3.  Current pharmacologic treatment for orthostatic hypotension.

Authors:  Roy Freeman
Journal:  Clin Auton Res       Date:  2008-03-27       Impact factor: 4.435

4.  Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice.

Authors:  Robert E Schmidt; Karen G Green; Dongyan Feng; Denise A Dorsey; Curtis A Parvin; Jin-Moo Lee; Qinlgi Xiao; Michael Brines
Journal:  Exp Neurol       Date:  2007-10-29       Impact factor: 5.330

5.  Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy.

Authors:  Martin Köllensperger; Florian Krismer; Anton Pallua; Nadia Stefanova; Werner Poewe; Gregor K Wenning
Journal:  Mov Disord       Date:  2011-01-06       Impact factor: 10.338

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.